Bladder cancer: Optimal application of preclinical models to suitable translational questions

Science Translational Medicine

Volumn 2, Issue 22, 2010, Pages

  Raghavan, Derek ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANDESARTAN; CISPLATIN; CYTOTOXIC AGENT; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; TELOMERASE; THYMIDINE PHOSPHORYLASE; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER LOCALIZATION; CANCER MODEL; CELL CYCLE; CELL GROWTH; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; DRUG EFFICACY; EXPERIMENTAL MODEL; GENE EXPRESSION; HUMAN; METASTASIS; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN STABILITY; SHORT SURVEY; TRANSLATIONAL RESEARCH; TUMOR CELL; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, BIOLOGICAL; TRANSLATIONAL RESEARCH; URINARY BLADDER NEOPLASMS;

EID: 77953015028     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3000215     Document Type: Short Survey

References (39)

1. D. Raghavan, W. U. Shipley, M. B. Garnick, P. J. Russell, J. P. Richie, Biology and management of bladder cancer. N. Engl. J. Med. 322, 1129-1138 (1990).
2. C. P. Dinney, D. J. McConkey, R. E. Millikan, X. Wu, M. Bar-Eli, L. Adam, A. M. Kamat, A. O. Siefker-Radtke, T. Tuziak, A. L. Sabichi, H. B. Grossman, W. F. Benedict, B. Czerniak, Focus on bladder cancer. Cancer Cell 6, 111-116 (2004).
3. J. L. Brown, P. J. Russell, J. Philips, J. Wotherspoon, D. Raghavan, Clonal analysis of a bladder cancer cell line: An experimental model of tumour heterogeneity. Br. J. Cancer 61, 369-376 (1990).
4. A. P. Mitra, R. H. Datar, R. J. Cote, Molecular pathways in invasive bladder cancer: New insights into mechanisms, progression, and target identification. J. Clin. Oncol. 24, 5552-5564 (2006).
5. R. F. Youssef, A. P. Mitra, G. Bartsch, Jr, P. A. Jones, D. G. Skinner, R. J. Cote, Molecular targets and targeted therapies in bladder cancer management. World J. Urol. 27, 9-20 (2009).
6. P. J. Russell, E. J. Wills, J. Philips, J. Wass, M. Jelbart, P. Gregory, D. Raghavan, Features of squamous and adenocarcinoma in the same cell in a xenografted human transitional cell carcinoma: Evidence of a common histogenesis? Urol. Res. 16, 79-84 (1988).
7. C. Shih, R. A. Weinberg, Isolation of a transforming sequence from a human bladder carcinoma cell line. Cell 29, 161-169 (1982).
8. C. Cordon-Cardo, G. Dalbagni, G. T. Saez, M. R. Oliva, Z. F. Zhang, J. Rosai, V. E. Reuter, A. Pellicer, p53 mutations in human bladder cancer: Genotypic versus phenotypic patterns. Int. J. Cancer 56, 347-353 (1994).
9. J. P. Stein, D. A. Ginsberg, G. D. Grossfeld, S. J. Chatterjee, D. Esrig, M. G. Dickinson, S. Groshen, C. R. Taylor, P. A. Jones, D. G. Skinner, R. J. Cote, Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J. Natl. Cancer Inst. 90, 1072-1079 (1998).
10. H. B. Grossman, R. B. Natale, C. M. Tangen, V. O. Speights, N. J. Vogelzang, D. L. Trump, R. W. DeVere White, M. F. Sarosdy, D. P. Wood Jr., D. Raghavan, E. D. Crawford, Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349, 859-866 (2003).
11. International Collaboration of Trialists on behalf of MRC Advanced Bladder Cancer Working Party, EORTC Genitourinary Group, Australian Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group, Finnbladder, Norwegian Bladder Cancer Study Group, Club Urologico Espanol de Tratamiento Oncologico (CUETO) group, Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: A randomized controlled trial. International collaboration of trialists. Lancet 354, 533-540 (1999).
12. A. Kovnat, R. N. Buick, J. G. Connolly, M. A. Jewett, A. G. Keresteci, I. F. Tannock, Comparison of growth of human bladder cancer in tissue culture or as xenografts with clinical and pathological characteristics. Cancer Res. 44, 2530-2533 (1984).
13. X. Fu, R. M. Hoff man, Human RT-4 bladder carcinoma is highly metastatic in nude mice and comparable to ras-Htransformed RT-4 when orthotopically onplanted as histologically intact tissue. Int. J. Cancer 51, 989-991 (1992).
14. M. J. Bailey, A. J. Jones, A. J. Shorthouse, D. Raghaven, P. Selby, J. Gibbs, M. J. Peckham, Limitations of the human tumour xenograft system in individual patient drug sensitivity testing. Br. J. Cancer 50, 721-724 (1984).
15. P. J. Russell, D. Raghavan, P. Gregory, J. Philips, E. J. Wills, M. Jelbart, J. Wass, R. A. Zbroja, P. C. Vincent, Bladder cancer xenografts: A model of tumor cell heterogeneity. Cancer Res. 46, 2035-2040 (1986).
16. P. J. Russell, M. Jelbart, E. Wills, S. Singh, J. Wass, J. Wotherspoon, D. Raghavan, Establishment and characterization of a new human bladder cancer cell line showing features of squamous and glandular differentiation. Int. J. Cancer 41, 74-82 (1988).
17. A. J. Grant, P. J. Russell, D. Raghavan, Elastase activities of human bladder cancer cell lines derived from high grade invasive tumours. Biochem. Biophys. Res. Commun. 162, 308-315 (1989).
18. A. J. Grant, P. J. Russell, D. Raghavan, Active and proplasminogen activator on the surface of human bladder cancer cells derived from a high grade invasive tumour. Biochem. Biophys. Res. Commun. 172, 870-876 (1990).
19. P. J. Russell, J. Wotherspoon, M. Jelbart, J. Philips, D. Raghavan, Stability of lectin binding properties expressed by human bladder carcinoma cell lines passaged in vitro or in nude mice. Urol. Res. 16, 407-414 (1988).
20. P. J. Russell, J. Philips, W. Allan, D. A. Hume, Antigenic variation and macrophage infiltration of human bladder tumors xenografted into nude mice. J. Leukoc. Biol. 43, 335-342 (1988).
21. 11-diethylnorspermine on a human bladder tumor xenograft in nude athymic mice. Clin. Cancer Res. 3, 1239-1244 (1997).
22. P. J. Russell, D. Raghavan, J. Philips, P. Gregory, Applications of the xenograft as a model of invasive transitional cell carcinoma of the bladder. Prog. Clin. Biol. Res. 260, 167-181 (1988).
23. D. Glaves, M. K. Murray, D. Raghavan, Novel bifunctional anthracycline and nitrosourea chemotherapy for human bladder cancer: Analysis in a preclinical survival model. Clin. Cancer Res. 2, 1315-1319 (1996).
24. L. Pendyala, S. Velagapudi, K. Toth, J. Zdanowicz, D. Glaves, H. Slocum, R. Perez, R. Huben, P. J. Creaven, D. Raghavan, Translational studies of glutathione in bladder cancer cell lines and human specimens. Clin. Cancer Res. 3, 793-798 (1997).
25. P. J. Russell, I. Ho Shon, G. R. Boniface, M. E. Izard, J. Philips, D. Raghavan, K. Z. Walker, Growth and metastasis of human bladder cancer xenografts in the bladder of nude rats. A model for intravesical radioimmunotherapy. Urol. Res. 19, 207-213 (1991).
26. C. P. Dinney, R. Fishbeck, R. Singh, B. Eve, S. Pathak, N. Brown, B. Xie, D. Fan, C. Bucana, I. Fidler, Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. J. Urol. 154, 1532-1538 (1995).
27. J. J. Mansure, R. Nassim, S. Chevalier, J. Rocha, E. Scarlata, W. Kassouf, Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer. Cancer Biol. Ther. 8, 2339-2347, (2009).
28. M. Kamada, A. So, M. Muramaki, P. Rocchi, E. Beraldi, M. Gleave, Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Mol. Cancer Ther. 6, 299-308 (2007).
29. W. Jian, H. Yamashita, J. M. Levitt, S. P. Lerner, G. Sonpavde, Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine. Mol. Cancer Ther. 8, 1772-1778 (2009).
30. S. B. Saxman, K. J. Propert, L. H. Einhorn, E. D. Crawford, I. Tannock, D. Raghavan, P. J. Loehrer Sr., D. L. Trump, Longterm follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J. Clin. Oncol. 15, 2564-2569 (1997).
31. D. Raghavan, An essay on rearranging the deck chairs: What's wrong with the cancer trials system? Clin. Cancer Res. 12, 1949-1950 (2006).
32. P. F. Thall, L. H. Wooten, C. J. Logothetis, R. E. Millikan, N. M. Tannir, Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring. Stat. Med. 26, 4687-4702 (2007).
33. R. Gray, J. Manola, S. Saxman, J. Wright, J. Dutcher, M. Atkins, M. Carducci, W. See, C. Sweeney, G. Liu, M. Stein, R. Dreicer, G. Wilding, R. S. DiPaola, Phase II clinical trial design: Methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group. Clin. Cancer Res. 12, 1966-1969 (2006).
34. H. E. Skipper, F. M. Schabel Jr., Tumor stem cell heterogeneity: Implications with respect to classification of cancers by chemotherapeutic effect. Cancer Treat. Rep. 68, 43-61 (1984).
35. P. C. Black, C. P. N. Dinney, Bladder cancer angiogenesis and metastasis-translation from murine model to clinical trial. Cancer Metastasis Rev. 26, 623-634 (2007).
36. K. S. Chan, I. Espinosa, M. Chao, D. Wong, L. Ailles, M. Diehn, H. Gill, J. Presti Jr., H. Y. Chang, M. Van de Rijn, L. Shortliffe, I. L. Weissman, Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc. Natl. Acad. Sci. U. S. A. 106, 14016-14021 (2009).
37. N. S. Brown, E. H. Streeter, A. Jones, A. L. Harris, R. Bicknell, Cooperative stimulation of vascular endothelial growth factor expression by hypoxia and reactive oxygen species: The effect of targeting vascular endothelial growth factor and oxidative stress in an orthotopic xenograft model of bladder carcinoma. Br. J. Cancer 92, 1696-1701 (2005).
38. D. Kunze, D. Wuttig, I. Kausch, C. Blietz, L. Blumhoff, Y. Burmeister, K. Kraemer, S. Fuessel, M. Toma, B. Schwenzer, A. Meye, M. O. Grimm, O. W. Hakenberg, D. Jocham, M. P. Wirth, Wirth, Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo. Int. J. Oncol. 32, 1049-1056 (2008).
39. M. Kosugi, A. Miyajima, E. Kikuchi, T. Kosaka, Y. Horiguchi, M. Murai, M. Oya, Angiotensin II type 1 receptor antagonist enhances cis- dichlorodiammineplatinum-induced cytotoxicity in mouse xenograft model of bladder cancer. Urology 73, 655-660 (2009).